Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)

BACKGROUND: Outcome of low-grade glioma (LGG, WHO grade II) is highly variable reflecting molecular heterogeneity of the disease. We compared two different single modality treatment strategies: standard radiotherapy (RT) versus primary temozolomide (TMZ) chemotherapy with the aim of tailoring treatm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Baumert, Brigitta G., Hegi, Monika E., van den Bent, Martin J., von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A., Kantor, Guy, Taphoorn, Martin J.B., Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M., Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E., Feuvret, Loic, Reijneveld, Jaap C., Chinot, Olivier, Gijtenbeek, Johanna M. M., Rossiter, John P., Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M., Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A., Rees, Jeremy, Lacombe, Denis, Mason, Warren P., Stupp, Roger
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5124485/
https://ncbi.nlm.nih.gov/pubmed/27686946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30313-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados